FrancophonIA/ELRC3.0 huggingface dataset:
English: Irbesartan Hydrochlorothiazide BMS 300 mg/12.5 mg may be administered in patients insufficiently controlled by irbesartan 300 mg or by Irbesartan Hydrochlorothiazide BMS 150 mg/12.5 mg.
Estonian: Irbesartan Hydrochlorothiazide BMS 300 mg/12,5 mg võib manustada patsientidele, kelle vererõhu kontrollimiseks 300 mg irbesartaani või Irbesartan Hydrochlorothiazide BMS 150 mg/12,5 mg ei ole piisav.
English: Cartons of 56 x 1 film-coated tablets; 7 blister cards of 8 x 1 film-coated tablets each in PVC/PVDC/Aluminium perforated unit dose blisters.
Estonian: Pakendis 56 x 1 õhukese polümeerikattega tabletti; 7 PVC/PVDC/Alumiinium blistrit 8 x 1 üheannuselises perforeeritud blisterpakendis.
English: Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg may be administered in patients insufficiently controlled by Irbesartan Hydrochlorothiazide BMS 300 mg/12.5 mg.
Estonian: Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg võib manustada patsientidele, kelle vererõhu kontrollimiseks Irbesartan Hydrochlorothiazide BMS 300 mg/12,5 mg ei ole piisav.
English: Exacerbation or activation of systemic lupus erythematosus has been reported with the use of thiazide diuretics.
Estonian: Tiasiid-diureetikumide kasutamisel on esinenud süsteemse erütematoosse luupuse ägenemist või aktiveerumist.
English: INFORMATION IN BRAILLE Irbesartan Hydrochlorothiazide BMS 300 mg/12.5 mg
Estonian: INFORMATSIOON BRAILLE' KIRJAS (PUNKTKIRJAS) Irbesartan Hydrochlorothiazide BMS 300 mg/12,5 mg
English: Cartons of 14 tablets; 1 blister card of 14 tablets in PVC/PVDC/Aluminium blisters.
Estonian: Pakendis 14 tabletti; 1 PVC/PVDC/Alumiinium blister 14 tabletiga.
English: Thiazide diuretic-associated azotemia may occur in patients with impaired renal function.
Estonian: Kahjustunud neerufunktsiooniga patsientidel võib esineda tiasiid-diureetikumidega seotud asoteemiat.
English: Cartons of 98 tablets; 7 blister cards of 14 tablets in PVC/PVDC/Aluminium blisters.
Estonian: Pakendis 98 tabletti; 7 PVC/PVDC/Alumiinium blistrit 14 tabletiga.
English: Each film-coated tablet of Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg contains 300 mg irbesartan and 25 mg hydrochlorothiazide.
Estonian: Iga Irbesartan Hydrochlorothiazide BMS 300 mg/ 25 mg õhukese polümeerikattega tablett sisaldab 300 mg irbesartaani ja 25 mg hüdroklorotiasiidi.
English: STATEMENT OF ACTIVE SUBSTANCES Each tablet contains: irbesartan 300 mg and hydrochlorothiazide 25 mg
Estonian: TOIMEAINETE SISALDUS Iga tablet sisaldab: 300 mg irbesartaani ja 25 mg hüdroklorotiasiidi.
English: Metabolism and nutrition disorders:
Estonian: Ainevahetus- ja toitumishäired: Teadmata:
English: Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is attenuated by the potassium-sparing effect of irbesartan.
Estonian: Kaaliumisisaldust mõjutavad preparaadid: hüdroklorotiasiidi kaaliumi väljutavat toimet tasakaalustab irbesartaani kaaliumi säästev toime.
English: Cartons of 84 film-coated tablets; 6 blister cards of 14 film-coated tablets in PVC/PVDC/Aluminium blisters.
Estonian: Pakendis 84 õhukese polümeerikattega tabletti; 6 PVC/PVDC/Alumiinium blistrit 14 õhukese polümeerikattega tabletiga.
English: Cartons of 28 tablets; 2 blister cards of 14 tablets in PVC/PVDC/Aluminium blisters.
Estonian: Pakendis 28 tabletti; 2 PVC/PVDC/Alumiinium blistrit 14 tabletiga.
English: EU/1/06/369/017 - 14 tablets EU/1/06/369/018 - 28 tablets EU/1/06/369/019 - 56 tablets EU/1/06/369/020 - 56 x 1 tablets EU/1/06/369/021 - 84 tablets EU/1/06/369/022 - 98 tablets
Estonian: EU/1/06/369/017 - 14 tabletti EU/1/06/369/018 - 28 tabletti EU/1/06/369/019 - 56 tabletti EU/1/06/369/020 - 56 x 1 tabletti EU/1/06/369/021 - 84 tabletti EU/1/06/369/022 - 98 tabletti
English: STATEMENT OF ACTIVE SUBSTANCES Each tablet contains: irbesartan 150 mg and hydrochlorothiazide 12.5 mg
Estonian: TOIMEAINETE SISALDUS Iga tablet sisaldab: 150 mg irbesartaani ja 12,5 mg hüdroklorotiasiidi.
English: Each tablet of Irbesartan Hydrochlorothiazide BMS 150 mg/12.5 mg contains 150 mg irbesartan and 12.5 mg hydrochlorothiazide.
Estonian: Iga Irbesartan Hydrochlorothiazide BMS 150 mg/ 12,5 mg tablett sisaldab 150 mg irbesartaani ja 12,5 mg hüdroklorotiasiidi.
English: Medicinal product subject to medical prescription
Estonian: RAVIMPREPARAADI NIMETUS
English: Cartons of 56 tablets; 4 blister cards of 14 tablets in PVC/PVDC/Aluminium blisters.
Estonian: Pakendis 56 tabletti; 4 PVC/PVDC/Alumiinium blistrit 14 tabletiga.
English: EU/1/06/369/011 - 14 tablets EU/1/06/369/012 - 28 tablets EU/1/06/369/013 - 56 tablets EU/1/06/369/014 - 56 x 1 tablets EU/1/06/369/015 - 84 tablets EU/1/06/369/016 - 98 tablets
Estonian: EU/1/06/369/011 - 14 tabletti EU/1/06/369/012 - 28 tabletti EU/1/06/369/013 - 56 tabletti EU/1/06/369/014 - 56 x 1 tabletti EU/1/06/369/015 - 84 tabletti EU/1/06/369/016 - 98 tabletti
English: Fri
Estonian: Annused
English: NAME OF THE MEDICINAL PRODUCT Irbesartan Hydrochlorothiazide BMS 150 mg/12.5 mg tablets.
Estonian: RAVIMPREPARAADI NIMETUS Irbesartan Hydrochlorothiazide BMS 150 mg/12,5 mg tabletid.
English: Irbesartan Hydrochlorothiazide BMS 150 mg/12.5 mg tablets are supplied in blister packs of 14, 28, 56 or 98 tablets.
Estonian: Irbesartan Hydrochlorothiazide BMS 150 mg/12,5 mg tabletid on pakendatud 14, 28, 56 või 98 tableti kaupa blisterpakendisse.
English: EU/1/06/369/023 - 14 tablets EU/1/06/369/024 - 28 tablets EU/1/06/369/025 - 56 tablets EU/1/06/369/026 - 56 x 1 tablets EU/1/06/369/027 - 84 tablets EU/1/06/369/028 - 98 tablets
Estonian: EU/1/06/369/023 - 14 tabletti EU/1/06/369/024 - 28 tabletti EU/1/06/369/025 - 56 tabletti EU/1/06/369/026 - 56 x 1 tabletti EU/1/06/369/027 - 84 tabletti EU/1/06/369/028 - 98 tabletti
English: dizziness
Estonian: köha
English: There is no clinical experience with Irbesartan Hydrochlorothiazide BMS in patients with hepatic impairment.
Estonian: Irbesartan Hydrochlorothiazide BMS'i kasutamise kohta maksakahjustusega patsientidel kliinilised kogemused puuduvad.
English: Each tablet of Irbesartan Hydrochlorothiazide BMS 300 mg/12.5 mg contains 300 mg irbesartan and 12.5 mg hydrochlorothiazide.
Estonian: Iga Irbesartan Hydrochlorothiazide BMS 300 mg/ 12,5 mg tablett sisaldab 300 mg irbesartaani ja 12,5 mg hüdroklorotiasiidi.
English: transient blurred vision, xanthopsia
Estonian: Teadmata mööduv hägusnägemine, ksantopsia
English: STATEMENT OF ACTIVE SUBSTANCES Each tablet contains: irbesartan 300 mg and hydrochlorothiazide 12.5 mg
Estonian: TOIMEAINETE SISALDUS Iga tablet sisaldab: 300 mg irbesartaani ja 12,5 mg hüdroklorotiasiidi.
English: When measured by ambulatory blood pressure monitoring, the trough to peak effects of Irbesartan Hydrochlorothiazide BMS 150 mg/12.5 mg were 100%.
Estonian: Ambulatoorsel vererõhumonitooringul oli Irbesartan Hydrochlorothiazide BMS'i 150 mg/12,5 mg minimaalse ja maksimaalse vererõhulanguse suhe 100%.
English: Irbesartan Hydrochlorothiazide BMS 300 mg/12.5 mg tablets are supplied in blister packs of 14, 28, 56 or 98 tablets.
Estonian: Irbesartan Hydrochlorothiazide BMS 300 mg/12,5 mg tabletid on pakendatud 14, 28, 56 või 98 tableti kaupa blisterpakendisse.
English: NAME OF THE MEDICINAL PRODUCT Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg tablets irbesartan/hydrochlorothiazide
Estonian: RAVIMPREPARAADI NIMETUS Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg tabletid irbesartaan/hüdroklorotiasiid
English: EU/1/06/369/001 - 14 tablets EU/1/06/369/002 - 28 tablets EU/1/06/369/003 - 56 tablets EU/1/06/369/004 - 56 x 1 tablets EU/1/06/369/005 - 98 tablets
Estonian: EU/1/06/369/001 - 14 tabletti EU/1/06/369/002 - 28 tabletti EU/1/06/369/003 - 56 tabletti EU/1/06/369/004 - 56 x 1 tabletti EU/1/06/369/005 - 98 tabletti
English: EU/1/06/369/006 - 14 tablets EU/1/06/369/007 - 28 tablets EU/1/06/369/008 - 56 tablets EU/1/06/369/009 - 56 x 1 tablets EU/1/06/369/010 - 98 tablets
Estonian: EU/1/06/369/006 - 14 tabletti EU/1/06/369/007 - 28 tabletti EU/1/06/369/008 - 56 tabletti EU/1/06/369/009 - 56 x 1 tabletti EU/1/06/369/010 - 98 tabletti
English: NAME OF THE MEDICINAL PRODUCT Irbesartan Hydrochlorothiazide BMS 300 mg/12.5 mg tablets.
Estonian: RAVIMPREPARAADI NIMETUS Irbesartan Hydrochlorothiazide BMS 300 mg/12,5 mg tabletid.
English: Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg film-coated tablets are supplied in blister packs of 14, 28, 56, 84 or 98 film-coated tablets.
Estonian: Irbesartan Hydrochlorothiazide BMS'i 300 mg/25 mg õhukese polümeerikattega tabletid on pakendatud 14, 28, 56, 84 või 98 tableti kaupa blisterpakendisse.
English: What Irbesartan Hydrochlorothiazide BMS looks like and contents of the pack Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg film-coated tablets are pink, biconvex, ovalshaped, with a heart debossed on one side and the number 2788 engraved on the other side.
Estonian: Kuidas Irbesartan Hydrochlorothiazide BMS välja näeb ja pakendi sisu Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg õhukese polümeerikattega tablett on roosa, kaksikkumer, ovaalne, sissepressitud südamekujuga ühel poolel ja sissegraveeritud number 2788 teisel poolel.
English: NAME OF THE MEDICINAL PRODUCT Irbesartan Hydrochlorothiazide BMS 150 mg/12.5 mg tablets irbesartan/hydrochlorothiazide
Estonian: RAVIMPREPARAADI NIMETUS Irbesartan Hydrochlorothiazide BMS 150 mg/12,5 mg tabletid irbesartaan/hüdroklorotiasiid
English: Cartons of 28 film-coated tablets; 2 blister cards of 14 film-coated tablets in PVC/PVDC/Aluminium blisters.
Estonian: Pakendis 28 õhukese polümeerikattega tabletti; 2 PVC/PVDC/Alumiinium blistrit 14 õhukese polümeerikattega tabletiga.
English: NAME OF THE MEDICINAL PRODUCT Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg film-coated tablets.
Estonian: RAVIMPREPARAADI NIMETUS Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg õhukese polümeerikattega tabletid.
English: Cartons of 14 film-coated tablets; 1 blister card of 14 film-coated tablets in PVC/PVDC/Aluminium blisters.
Estonian: Pakendis 14 õhukese polümeerikattega tabletti; 1 PVC/PVDC/Alumiinium blister 14 õhukese polümeerikattega tabletiga.
English: Cartons of 56 film-coated tablets; 4 blister cards of 14 film-coated tablets in PVC/PVDC/Aluminium blisters.
Estonian: Pakendis 56 õhukese polümeerikattega tabletti; 4 PVC/PVDC/Alumiinium blistrit 14 õhukese polümeerikattega tabletiga.
English: Cartons of 98 film-coated tablets; 7 blister cards of 14 film-coated tablets in PVC/PVDC/Aluminium blisters.
Estonian: Pakendis 98 õhukese polümeerikattega tabletti; 7 PVC/PVDC/Alumiinium blistrit 14 õhukese polümeerikattega tabletiga.
English: What Irbesartan Hydrochlorothiazide BMS looks like and contents of the pack Irbesartan Hydrochlorothiazide BMS 150 mg/12.5 mg tablets are peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2775 engraved on the other side.
Estonian: Kuidas Irbesartan Hydrochlorothiazide BMS välja näeb ja pakendi sisu Irbesartan Hydrochlorothiazide BMS 150 mg/12,5 mg tablett on virsikuvärvi, kaksikkumer, ovaalne, sissepressitud südamekujuga ühel poolel ja sissegraveeritud number 2775 teisel poolel.
English: NAME OF THE MEDICINAL PRODUCT Irbesartan Hydrochlorothiazide BMS 300 mg/12.5 mg tablets irbesartan/hydrochlorothiazide
Estonian: RAVIMPREPARAADI NIMETUS Irbesartan Hydrochlorothiazide BMS 300 mg/12,5 mg tabletid irbesartaan/hüdroklorotiasiid
English: PACKAGE LEAFLET: INFORMATION FOR THE USER Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg film-coated tablets irbesartan/hydrochlorothiazide
Estonian: PAKENDI INFOLEHT: INFORMATSIOON KASUTAJALE Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg õhukese polümeerikattega tabletid irbesartaan/hüdroklorotiasiid
English: Irbesartan Hydrochlorothiazide BMS 150 mg/12.5 mg film-coated tablets are supplied in blister packs of 14, 28, 56, 84 or 98 film-coated tablets.
Estonian: Irbesartan Hydrochlorothiazide BMS'i 150 mg/12,5 mg õhukese polümeerikattega tabletid on pakendatud 14, 28, 56, 84 või 98 tableti kaupa blisterpakendisse.
English: What Irbesartan Hydrochlorothiazide BMS contains The active substances are irbesartan and hydrochlorothiazide.
Estonian: Toimeained on irbesartaan ja hüdroklorotiasiid.
English: What Irbesartan Hydrochlorothiazide BMS looks like and contents of the pack Irbesartan Hydrochlorothiazide BMS 300 mg/12.5 mg tablets are peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2776 engraved on the other side.
Estonian: Kuidas Irbesartan Hydrochlorothiazide BMS välja näeb ja pakendi sisu Irbesartan Hydrochlorothiazide BMS 300 mg/12,5 mg tablett on virsikuvärvi, kaksikkumer, ovaalne, sissepressitud südamekujuga ühel poolel ja sissegraveeritud number 2776 teisel poolel.
English: PACKAGE LEAFLET: INFORMATION FOR THE USER Irbesartan Hydrochlorothiazide BMS 150 mg/12.5 mg tablets irbesartan/hydrochlorothiazide
Estonian: PAKENDI INFOLEHT: INFORMATSIOON KASUTAJALE Irbesartan Hydrochlorothiazide BMS 150 mg/12,5 mg tabletid irbesartaan/hüdroklorotiasiid
English: What Irbesartan Hydrochlorothiazide BMS looks like and contents of the pack Irbesartan Hydrochlorothiazide BMS 150 mg/12.5 mg film-coated tablets are peach, biconvex, ovalshaped, with a heart debossed on one side and the number 2875 engraved on the other side.
Estonian: Kuidas Irbesartan Hydrochlorothiazide BMS välja näeb ja pakendi sisu Irbesartan Hydrochlorothiazide BMS 150 mg/12,5 mg õhukese polümeerikattega tablett on virsikuvärvi, kaksikkumer, ovaalne, sissepressitud südamekujuga ühel poolel ja sissegraveeritud number 2875 teisel poolel.
English: Irbesartan Hydrochlorothiazide BMS 300 mg/12.5 mg film-coated tablets are supplied in blister packs of 14, 28, 56, 84 or 98 film-coated tablets.
Estonian: Irbesartan Hydrochlorothiazide BMS'i 300 mg/12,5 mg õhukese polümeerikattega tabletid on pakendatud 14, 28, 56, 84 või 98 tableti kaupa blisterpakendisse.
English: PACKAGE LEAFLET: INFORMATION FOR THE USER Irbesartan Hydrochlorothiazide BMS 300 mg/12.5 mg tablets irbesartan/hydrochlorothiazide
Estonian: PAKENDI INFOLEHT: INFORMATSIOON KASUTAJALE Irbesartan Hydrochlorothiazide BMS 300 mg/12,5 mg tabletid irbesartaan/hüdroklorotiasiid
English: FOR
Estonian: L
English: What Irbesartan Hydrochlorothiazide BMS looks like and contents of the pack Irbesartan Hydrochlorothiazide BMS 300 mg/12.5 mg film-coated tablets are peach, biconvex, ovalshaped, with a heart debossed on one side and the number 2876 engraved on the other side.
Estonian: Kuidas Irbesartan Hydrochlorothiazide BMS välja näeb ja pakendi sisu Irbesartan Hydrochlorothiazide BMS 300 mg/12,5 mg õhukese polümeerikattega tablett on virsikuvärvi, kaksikkumer, ovaalne, sissepressitud südamekujuga ühel poolel ja sissegraveeritud number 2876 teisel poolel.
English: NAME OF THE MEDICINAL PRODUCT Irbesartan Hydrochlorothiazide BMS 150 mg/12.5 mg film-coated tablets.
Estonian: RAVIMPREPARAADI NIMETUS Irbesartan Hydrochlorothiazide BMS 150 mg/12,5 mg õhukese polümeerikattega tabletid.
English: NAME OF THE MEDICINAL PRODUCT Irbesartan Hydrochlorothiazide BMS 300 mg/12.5 mg film-coated tablets.
Estonian: RAVIMPREPARAADI NIMETUS Irbesartan Hydrochlorothiazide BMS 300 mg/12,5 mg õhukese polümeerikattega tabletid.
English: NAME OF THE MEDICINAL PRODUCT Irbesartan Hydrochlorothiazide BMS 150 mg/12.5 mg film-coated tablets irbesartan/hydrochlorothiazide
Estonian: Irbesartan Hydrochlorothiazide BMS 150 mg/12,5 mg õhukese polümeerikattega tabletid irbesartaan/hüdroklorotiasiid
English: NAME OF THE MEDICINAL PRODUCT Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg film-coated tablets irbesartan/hydrochlorothiazide
Estonian: Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg õhukese polümeerikattega tabletid irbesartaan/hüdroklorotiasiid
English: flushing
Estonian: pearinglus
English: The European Commission granted a marketing authorisation valid throughout the EU for Biograstim to CT Arzneimittel GmbH on 15 September 2008.
Estonian: Euroopa Komisjon väljastas Biograstimi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele CT Arzneimittel GmbH 15. septembril 2008.
English: This means that Biograstim is similar to a biological medicine that is already authorised in the European Union (EU) and contains the same active substance (also known as the ‘reference medicine').
Estonian: See tähendab, et Biograstim on sarnane bioloogilise ravimiga, millel on juba Euroopa Liidus müügiluba ning mis sisaldab sama toimeainet (nimetatakse ka võrdlusravimiks).
English: The Committee recommended that Biograstim be given marketing authorisation.
Estonian: Komitee soovitas anda Biograstimile müügiloa.
English: Other information about Biograstim:
Estonian: Muu teave Biograstimi kohta
English: To study the safety of Biograstim, two further studies were carried out in patients with lung cancer and with non-Hodgkin's lymphoma.
Estonian: Biograstimi ohutuse uurimiseks viidi läbi veel kaks täiendavat uuringut patsientidel, kellel oli kopsuvähk ja mitte-Hodgkini lümfoom.
English: Biograstim can also be used in patients who are about to donate blood stem cells for transplant, to help release these cells from the bone marrow.
Estonian: Lisaks võib Biograstimit kasutada patsientidel, kes hakkavad loovutama siirdamiseks vere tüvirakke, et aidata nendel rakkudel luuüdist vabaneda.
English: During the first 21-day chemotherapy cycle, patients treated with either Biograstim or Neupogen had severe neutropenia for an average of 1.1 days, compared with 3.8 days in those receiving placebo.
Estonian: Esimese 21-päevase keemiaravitsükli jooksul oli kas Biograstimiga või Neupogeniga ravitud patsientidel raske neutropeenia keskmiselt 1,1 päeva võrreldes 3,8 päevaga neil patsientidel, kes said platseebot.
English: Biograstim is usually given in a specialised treatment centre, although patients who receive it by injection under the skin may inject themselves once they have been trained appropriately.
Estonian: Biograstimit manustatakse tavaliselt spetsiaalses ravikeskuses, kuigi patsiendid, kellele seda manustatakse nahaaluse süstena, võivad pärast asjakohase väljaõppe saamist süstida end ise.
English: Biograstim should not be used in people who may be hypersensitive (allergic) to filgrastim or any of the other ingredients.
Estonian: Biograstimit ei tohi kasutada patsiendid, kes võivad olla ülitundlikud (allergilised) filgrastiimi või selle ravimi mis tahes muu koostisaine suhtes.
English: Other side effects may be seen in more than 1 patient in 10, depending on the condition that Biograstim is being used for.
Estonian: Muud kõrvalnähud võivad esineda enam kui ühel patsiendil kümnest olenevalt haigusseisundist, mille ravimiseks Biograstimit kasutatakse.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) BIOGRASTIM EPAR summary for the public
Estonian: EUROOPA AVALIK HINDAMISARUANNE BIOGRASTIM Kokkuvõte üldsusele
English: The active substance in Biograstim, filgrastim, is very similar to a human protein called granulocyte colony stimulating factor (G-CSF).
Estonian: Biograstimi toimeaine filgrastiim on väga sarnane inimvalguga, mida nimetatakse granülotsüütide kolooniaid stimuleerivaks teguriks (G-CSF).
English: Biograstim was compared to Neupogen and to placebo (a dummy treatment) in one main study involving 348 patients with breast cancer.
Estonian: Biograstimit võrreldi Neupogeniga ja platseeboga (näiv ravim) ühes põhiuuringus, kus osales 348 rinnavähiga patsienti.
English: The Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements, Biograstim has been shown to have a comparable quality, safety and efficacy profile to Neupogen.
Estonian: Inimravimikomitee jõudis otsusele, et Euroopa Liidu nõuete kohaselt on tõendatud, et Biograstimi kvaliteedi, ohutuse ja tõhususe profiil on samaväärne Neupogeni omaga.
English: Biograstim is used to stimulate the production of white blood cells in the following situations:
Estonian: Biograstimit kasutatakse valgeliblede tekkimise stimuleerimiseks järgmistel juhtudel:
English: The most common side effect with Biograstim (seen in more than 1 patient in 10) is musculoskeletal pain (pain in the muscles and bones).
Estonian: Biograstimi kõige sagedam kõrvalnäht (esinenud enam kui ühel patsiendil kümnest) on luu-lihaskonna valu.
English: Therefore, the effectiveness of Biograstim was shown to be equivalent to that of Neupogen.
Estonian: Seega tõendati, et Biograstimi efektiivsus on samaväärne Neupogeni efektiivsusega.
English: Treatment with Biograstim and Neupogen brought about similar reductions in duration of severe neutropenia.
Estonian: Ravi Biograstimiga ja ravi Neupogeniga vähendasid raske neutropeenia kestust sarnasel määral.
English: Therefore, the CHMP's view was that, as for Neupogen, the benefit outweighs the identified risk.
Estonian: Seetõttu leidis inimravimikomitee, et nagu ka Neupogeni puhul, ületab Biograstimist saadav kasulikkus ilmnenud riskid.
English: What is the risk associated with Biograstim?
Estonian: Mis riskid Biograstimiga kaasnevad?
English: What is Biograstim?
Estonian: Mis on Biograstim?
English: Why has Biograstim been approved?
Estonian: Miks Biograstim heaks kiideti?
English: For the full list of all side effects reported with Biograstim, see the Package Leaflet.
Estonian: Biograstimi kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: Biograstim is a solution for injection or for infusion (drip into a vein).
Estonian: Biograstim on süstelahus või infusioonilahus (veeni tilgutatav lahus).
English: Biograstim was studied to show that it is comparable to the reference medicine, Neupogen.
Estonian: Biograstimit uuriti selle ravimi samaväärsuse tõendamiseks võrdlusravimiga Neupogen.
English: Biograstim is given by injection under the skin or infusion into a vein.
Estonian: Biograstimit manustatakse nahaaluse süstega või infusiooniga veeni.
English: The full EPAR for Biograstim can be found here.
Estonian: Euroopa avaliku hindamisaruande täisteksti Biograstimi kohta leiate siit.
English: Biograstim is a ‘biosimilar' medicine.
Estonian: Biograstim on bioloogiliselt sarnane ravim.
English: How has Biograstim been studied?
Estonian: Kuidas Biograstimit uuriti?
English: Filgrastim is produced by a method known as ‘recombinant DNA technology': it is made by a bacterium that has received a gene (DNA), which makes it able to produce filgrastim.
Estonian: seda toodab bakter, millele on lisatud filgrastiimi teket võimaldav geen (DNA).
English: How is Biograstim used?
Estonian: Kuidas Biograstimit kasutatakse?
English: What is Biograstim used for?
Estonian: Milleks Biograstimit kasutatakse?
English: What benefit has Biograstim shown during the studies?
Estonian: Milles seisneb uuringute põhjal Biograstimi kasulikkus?
English: How does Biograstim work?
Estonian: Kuidas Biograstim toimib?
English: The reference medicine for Biograstim is Neupogen.
Estonian: Biograstimi võrdlusravim on Neupogen.
English: No If Yes, write the names of these here:
Estonian: □ Ei Kui jah, kirjutage siia nende nimetused:
English: Date of first authorisation: 15 May 2002 Date of latest renewal: 20 April 2012
Estonian: Müügiloa esmase väljastamise kuupäev: 15. mai 2002 Müügiloa viimase uuendamise kuupäev: 20. aprill 2012
English: Your name: __________________________________________________ Prescribing doctor: ________________________________________ If you have questions about Tracleer ask your doctor.
Estonian: Teie nimi: __________________________________________________ Ravi määranud arst: __________________________________________ Kui teil on Tracleer'i kohta küsimusi, pöörduge oma arsti poole.
English: 56 dispersible tablets (14 x 4)
Estonian: 56 dispergeeruvat tabletti (14 x 4)
English: This card contains important information about Tracleer.
Estonian: Käesolev kaart sisaldab tähtsat teavet Tracleer'i kohta.
English: Other medicines and Tracleer
Estonian: Muud ravimid ja Tracleer
English: Tracleer with food and drink
Estonian: Tracleer koos toidu ja joogiga
English: Push the pharmaceutical product through the foil.
Estonian: Suruge ravimtoode läbi fooliumi.
English: Please read this card carefully before starting your treatment with Tracleer.
Estonian: Palun lugege see kaart enne ravi alustamist Tracleer'iga hoolikalt läbi.
English: Leave for about one minute, until the tablet has fully dissolved, and then swallow all of the liquid.
Estonian: Oodake umbes minut, kuni tablett on täielikult lahustunud ja siis neelake kogu vedelik alla.